Cellectis Stock Rises 4% This Morning After a 18% Drop Over the Quarter
Cellectis is seeing a rebound this Friday, April 10, with its shares trading at €3.158 mid-morning, up more than 4% from the previous day. This recovery comes amidst a challenging quarter for the French biotech, with a decline of over 18% over three months.
Current Trading Status
Cellectis shares are trading at €3.158 this morning, up from €3.04 at the previous close. The weekly performance remains modestly positive (+1.71%), but the quarterly record is still heavily negative at -18.19%. In the longer term, however, the stock has shown a remarkable increase of 180.5% over the past year, indicating a volatile trajectory. Technically, the RSI at 35 places the stock in a weak zone, yet not crossing into the oversold threshold set at 30. The price is in the lower part of the Bollinger Bands, at 34% of the range between the lower bound (€2.90) and the upper bound (€3.65), indicating that selling pressure remains dominant in recent weeks. The most relevant support is at €2.93, a level that the stock has not breached during its recent decline.
Market Context of the Morning Rise
This morning's upward movement occurs in a generally calm market environment. The CAC 40 is up 0.26% during the session, at 8,267 points, while the SBF 120 has gained 0.29%. In the healthcare sector, Sanofi is up by 0.52% and UCB by 0.96%, suggesting a slightly favorable tone for the sector's stocks. Cellectis, specializing in cellular therapies through gene-editing (TALEN), remains a highly volatile stock: its volatility reaches 24.96 over a month. Its negative beta of -0.62 also indicates an unusual decorrelation from the overall market. The stock is currently trading below its 20-day (€3.27) and 50-day (€3.36) moving averages, but remains above the 200-day average (€2.94), which has acted as a support zone in recent weeks.
